Podcasts about blood disorders

On April 1st, the Administration announced drastic changes and reductions to the federal health programs, one being the Division of Blood Disorders CDC, greatly affecting the bleeding disorders community. To discuss these concerns, we welcome a familiar face to many of you - Johanna Gray, federal policy advisor to NBDF and all-around wonderful human.    Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Show Notes: Subscribe: The BloodStream Podcast   The CDC cuts are of particular concern to our community. The Division of Blood Disorders' work traces back to the 1980s' tainted blood crisis, when CDC investigators were the first to discern and warn of HIV's transmissibility through blood and blood products. To this day, the Division serves the bleeding disorders community and the nation at large through its public health surveillance activities – including maintaining a laboratory with blood samples dating back to 1996. The Division also funds the collection of key data on bleeding disorders through its “Community Counts” program, and supports educational outreach to increase patient and provider understanding of hemophilia and its complications. Elimination of the Division, its clinical repository, and its institutional knowledge would be a huge loss for the bleeding disorders community. WHAT CAN YOU DO?   Call the Capitol switchboard: (202) 224-3121  *Anyone can call this number and get connected with their Senators and Representative. I am calling as a member of the bleeding disorders community and as a constituent to ask that you protect the federal hemophilia programs at the CDC. The recent HHS restructuring eliminated essentially all of the staff at the CDC's Division of Blood Disorders, where the hemophilia programs are housed. These programs:   Help to collect important data on bleeding disorders which in turn helps lead to new and more effective treatments. Provide funding for education and outreach to increase patient and provider understanding of hemophilia. Help to protect the safety of our nation's blood supply.   I'm very worried about what this means for people with bleeding disorders and our country. Please work to restore the staffing and activities of the CDC Division of Blood Disorders.   I am relying on you, as my Senator/Representative in Congress, to take action to ensure that the staff for this program are reinstated and to work to protect the funding for this critical program. ** For years, people with hemophilia A waited for a cure, while inhibitor patients were left behind—but now, after setbacks and failed launches of several gene therapies, investors think patients aren't interested.  By taking this short survey, you can make your voice heard and show investors that our community still wants a durable gene therapy, but this time for both hemophilia A with or without inhibitors. Take the survey here   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Matasar, MD When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse events is a key consideration. Models such as PhasED-Seq and CAR-HEMATOTOX can help clinicians assess the patient's risk and personalize care plans regarding treatment selection and location, prophylactic regimen, and early intervention strategies. Tune in to hear Dr. Charles Turck and Dr. Matthew Matasar discuss the importance of these models in identifying individual factors, which can maximize the benefits of CAR T-cell therapy and reduce toxicities. Dr. Matasar is the Chief of the Division of Blood Disorders at Rutgers Cancer Institute and a Professor of Medicine at Rutgers Robert Wood Johnson Medical School.

In this episode of Hema Now, Jonathan Sackier welcomes Christopher Patriquin, a leading expert in the field of hematology and rare diseases. With a wealth of experience in teaching, consulting, clinical research, and hosting excellent dinner parties, Patriquin's discussion sheds light on many fascinating topics.    Timestamps:  (00:00)-Introduction  (02:00)-Dogs and dinner parties   (05:23)-Diagnosing and treating rare diseases  (09:42)-Cognitive decline in TTP survivors  (13:01)-Complement component 3 PNH therapy  (16:04)-Importance of apheresis medicine  (23:34)-The International PNH Registry  (26:52)-Developments in hematology  (28:56)-Equity and equality in access to care  (31:25)-Christopher's three wishes 

CME credits: 1.00 Valid until: 09-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-insights-into-rare-blood-disorders-diagnosis-and-treatment-strategies/16630/ Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it's essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine. In this activity, composed of 3 podcasts, an expert moderator will interview 3 expert faculty members about evidence-based guidelines for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura, developments in the diagnosis and treatment of cold agglutinin disease, and the challenges of achieving enduring remission in patients with immune thrombocytopenia.=

Safe and effective for everyone.....yup. Buy Outright Bars HERE! https://www.tigerfitness.com/products/mts-nutrition-outright-bar?variant=39556275044410

Justin talks with Floyd Brown about how to fight the battles in your life and for the future of this country from a place of victory. Floyd G. Brown is the founder of The Western Journal and the author of several books, including "Counterpunch" and "Big Tech Tyrants."Get the links to each show here: http://JustinBarclay.comGet up to $10,000 in free silver with qualified accounts from my new partners at Goldco!Go to JustinLikesGold.com to get a free 2024 Gold Kit or call 855.512.GOLD (4653) #goldopartnerTry Cue Streaming for just $2 / day and help support the good guys https://justinbarclay.com/cueUp to 80% OFF! Use promo code JUSTIN http://MyPillow.com/JustinPatriots are making the Switch! What if we could start voting with our dollars too? http://SwitchWithJustin.comNo matter what's coming, you can be ready for your family and others. http://PrepareWithJustin.com#ad

Unlock the mysteries of iron and its pivotal role in our health, as Dr. Marwa Farooqui from the University of Illinois Hospital and Health Sciences System takes us through the latest in iron supplementation and blood disorder care. Grapple with the complexities of iron absorption in those with chronic conditions and peripartum individuals, and learn how certain dietary choices can enhance or impede iron uptake. Dr. Farooqui illuminates the re-emergence of iron dextran in IV treatments, the progress in oral iron therapy, and introduces us to ferric maltol—a game-changer with minimal side effects. Through her lens, we navigate the delicate balance of iron in the body and confront the risks associated with iron overload in specific diseases.Transition with us from the cellular level to the comprehensive well-being of patients battling blood cancers. Dr. Farooqui underscores the crucial role of open dialogue, the undeniable impact of lifestyle choices on disease management and prevention, and the importance of family in patient advocacy. Together, we peer into the future of hematology, pondering the innovations on the horizon and the promise they hold. This episode is not just a conversation; it's a journey through the transformative landscape of survivorship care, offering empowering knowledge for anyone touched by these conditions.Support the show

Guest: Nicole Vanderpool SAA-Denver Event Co-Director Swim Across America is a national non-profit that runs swimming-related events throughout the country to support cancer research at the most highly recognized hospitals and institutions.  Over the years they have raised over $100MM for cancer research that stays locally.  Swim Across America's Denver has raised over $1 MM since 2018 and their beneficiary is Center for Cancer and Blood Disorders at Children's Hospital Colorado.  Their big event this year is going to be on August 20th at Chatfield Reservoir.  You register to swim anywhere from half a mile to two miles.  If you are over 18 the fundraising minimum is $500 and $250 if you are under 18.  https://www.swimacrossamerica.org/site/TR/OpenWater/Denver?pg=entry&fr_id=6591

Tune in to the Hematopoiesis podcast to hear a conversation about the increasingly relevant topic of geriatric hematology. Many blood disorders and hematologic malignancies are diseases of older adults, and in this introduction to geriatric hematology, Drs. Maya Abdallah and Ajay Major talk about “staging the aging.”Music: “Somebody New” RYYZN (www.toneden.io/ryyzn/post/somebody-new-copyright-free). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/.

WarRoom Battleground EP 333: Rise Of Blood Disorders In Europe Following 2020

In this episode, we talk to Ariela Marshall, a hematologist specializing in disorders of thrombosis and hemostasis (bleeding and clotting) in women. In this interview, we discuss blood thinners, the role of estrogen in blood clots and disorders of thrombosis and hemostasis throughout a woman's life.Remember to like, rate and subscribe and enjoy the episode!Guest bioDr. Marshall is a hematologist specializing in disorders of thrombosis and hemostasis (bleeding and clotting) in women.  She is a graduate of Harvard Medical School and completed her residency in Internal Medicine at the University of Pennsylvania followed by a fellowship in hematology-oncology at Dana Farber Cancer Institute/Massachusetts General Hospital.  She worked as a hematologist at Mayo Clinic in Rochester Minnesota from 2015-2021 and in 2021 she moved to Philadelphia to became the Director of Women's Thrombosis and Hemostasis at the University of Pennsylvania.  Dr. Marshall is currently planning to move back to Minnesota in summer 2023 and will establish educational platforms and advocacy initiatives centered on women's health, particularly women's blood disorders.  In addition to her clinical work, Dr. Marshall is a medical educator with a focus on career development, leadership, mentorship, and work-life integration.  She has a particular interest in gender equity for patients as well as for physicians.  She leads several national advocacy initiatives, co-chairs several national working groups and task forces, and speaks regularly on a national scope to discuss her efforts to advance fertility/infertility awareness, parental health, and gender equity.  FemTech Focus Podcast bioThe FemTech Focus Podcast is brought to you by FemHealth Insights, the leader in Women's Health market research and consulting. In this show, Dr. Brittany Barreto hosts meaningfully provocative conversations that bring FemTech experts - including doctors, scientists, inventors, and founders - on air to talk about the innovative technology, services, and products (collectively known as FemTech) that are improving women's health and wellness. Though many leaders in FemTech are women, this podcast is not specifically about female founders, nor is it geared toward a specifically female audience. The podcast gives our host, Dr. Brittany Barreto, and guests an engaging, friendly environment to learn about the past, present, and future of women's health and wellness.FemHealth Insights bioLed by a team of analysts and advisors who specialize in female health, FemHealth Insights is a female health-specific market research and analysis firm, offering businesses in diverse industries unparalleled access to the comprehensive data and insights needed to illuminate areas of untapped potential in the nuanced women's health market.Time Stamps[04:10] Ariela's background[06:00] Definitions - hematology, hemostasis and thrombosis[07:52] How does bleeding and clotting affect women?[09:25] Disorders in younger women[11:50] Contraception[13:06] Blood clots[20:39] Blood thinning[22:58] Sex specific recommendations [24:24] The role of estrogen in blood clots[30:40] Bleeding and risk factors for menopausal women[32:33] Bleeding PSA's for women's health[36:48] What's an area of women's health and wellness that still needs innovating?[38:03] Insurance for blood thinners[38:58] What does the femtech industry as a whole need the most right now in order to be successful?[39:37] Are medical schools starting to have the conversation about sex as a biological variable?Call to Action!Don't forget to subscribe to the FemTech Focus podcast, and leave us a review!Episode ContributorsDr. Ariela MarshallLinkedIn: @Ariela Marshall, MDTwitter: @AMarshallMD Dr. Brittany BarretoLinkedIn:  @Brittany Barreto, Ph.D.Twitter: @DrBrittBInstagram: @drbrittanybarreto FemTech Focus PodcastWebsite: https://femtechfocus.org/LinkedIn: https://www.linkedin.com/company/femtechfocusTwitter: @FemTech_FocusInstagram: @femtechfocus FemHealth InsightsWebsite: https://www.femhealthinsights.com/LinkedIn: @FemHealth Insights

Synopsis: Kate Haviland is the CEO of Blueprint Medicines, a global precision therapy company that creates life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, they create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Kate discusses beginning her career at Genzyme before joining Blueprint Medicines, and what the transition to becoming CEO was like after having held various different roles at Blueprint. She also talks about how personalized medicine is transforming patient care, and the company's focus on applying precision medicine to cancer and hematologic diseases. Finally, she dives into how the current environment informs how she approaches leading a publicly traded biotech and her perspective on partnerships. Interested in learning more? Check out their recent approval here: https://rb.gy/4126e Biography: Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. Since April 2022, Kate has served as Chief Executive Officer of Blueprint Medicines. Kate joined Blueprint in 2016 as Chief Business Officer and later served as Chief Operating Officer, where she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy, corporate development, commercial strategy, international, technical operations, corporate affairs, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics and is a member of the audit and compensation committees.

Dr. Leslie Appiah is a Professor of Obstetrics and Gynecology and Chief of the Division of Academic Specialists in Obstetrics and Gynecology at The University of Colorado School of Medicine and Children's Hospital Colorado. She is a fellowship-trained pediatric and adolescent gynecologist and Director of the Fertility Preservation and Reproductive Late Effects program at the Comprehensive Cancer Center and Center for Cancer and Blood Disorders. Dr. Appiah's clinical and research interests include team science and outcomes research in pediatric, adolescent, and young adult fertility preservation, reproductive late effects in cancer survivorship, and hormone replacement therapy in the medically complex patient. She is passionate about improving the health of girls and women so that they may pursue life, career, and education unencumbered by reproductive health concerns. She is also an alumnus of our Get That Grant® coaching program!Listen in as we discuss her coaching journey and: How to say NO with pleasure, peace, and confidence as a leader with many varying responsibilitiesHow keying into her energy balance has improved her productivity and leadership ability How she *finally* shifted away from the strategy she learned in every other coaching experience and found greater balance AND impactHer advice to mid and senior-level academics thinking about coaching and want to experience a similar transformation as she did  Loved this convo? Please go find Dr. Appiah and show her some love on Twitter @DrLeslieAppiah and Instagram @drleslieappiahIf you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations.

A transcript is available onlineSickle cell disease is an inherited disorder of the blood protein hemoglobin. It has multiple ways to impact the health of someone with the disease — with a hallmark symptom being excruciating chronic pain. The vast majority of people with sickle cell trait and sickle cell disease are Black. Until relatively recently, there has been only one drug to treat the disease.On this week's program, host Seán Collins talks with Dr. Titilope Fasipe, co-director of the Sickle Cell and Thalassemia Program at Texas Children's Cancer and Hematology Center in Houston about advances in both the treatment of sickle cell disease and progress toward a cure..Titilope Fasipe, M.D., Ph.D.Co-DirectorSickle Cell & Thalassemia ProgramTexas Children's Cancer & Hematology CenterAssistant ProfessorPediatrics & Hematology/OncologyBaylor College of MedicineHouston, Texas.To produce this episode, we collected stories from people living with sickle cell disease. These interviews are excerpted in this podcast episode and we invite you to listen to more of the conversations by following the links below. Andre Marcel Harris speaks with his sister Alexis HarrisSijaama Branch talking with producer Scott AcordHeather Avant in conversation with her cousin Dr. Bria Davis   ..To learn more:A full list of resources is available on our websiteSickle Cell & Thalasemmia Program   (Texas Children's)Sickle Cell Disease CoalitionA “Narcotics Contract” for a Patient With Sickle Cell Disease   Pediatrics / (the "care-seeking" article) Building access to care in adult sickle cell disease  Blood AdvancesCure Sickle Cell Initiative  NIHSickle Cell Gene Therapy Education Project   NIHAddressing SCD: A Strategic Plan and Blueprint for Action   NASEMA Review of Sickle Cell Disease (and Reply) JAMAHospital Use and Mortality in Transition-Aged Patients With Sickle Cell Disease  Hospital PediatricsStill seeking balance in opioid management for acute sickle cell disease pain   Pediatric Blood & Cancer..   

You're in for a treat, WITH listeners! Have you ever interacted with a doctor and asked yourself, "how can I clone this provider so everyone can have this great experience?"  Well, I have and this is the doctor I wish every single person receiving medical care could receive it from. Dr. Gregory Yanik is the Director of the Pediatric Blood and Marrow Transplant Program at the University of Michigan Medical Center in Ann Arbor, Michigan. From the moment you press play, you will hear why he's the GOAT. This is a can't miss episode. 

As part of the Between the Lines™ video series, Bruce Cheson, MD, FACP, FAAAS, FASCO, a board certified hematologist at the Center for Cancer and Blood Disorders in Bethesda, Maryland, spoke with Steven Park, MD, an oncologist and vice chair of Research at the Atrium Health Levine Cancer Institute and a clinical professor of Medicine at Wake Forest University. These experts shared their insight on the phase 1/2 E7438-G000-101 (NCT01897571) clinical trial and highlighted key data on tazemetostat (Tazverik), an EZH2 inhibitor, in relapsed or refractory follicular lymphoma. In the video series, Cheson and Park discussed the following: ·      Overview of relapsed/refractory follicular lymphoma and available treatment options ·      Tazemetostat trial data and propensity score-matched analysis ·      Role of tazemetostat treatment moving forward Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available. 

While in many parts of the world, a child living with blood disorders such as thalassemia or sickle cell anemia can practically live a normal life, in most of India they may not survive up to adulthood. This is because of a lack of regular blood supply and monitored treatment for these children.  In this episode Suno India's Menaka Rao speaks to people who suffer from blood disorders such as thalassaemia and sickle cell disease in rural Jharkhand and Chhattisgarh, and doctors and experts who work with these children.  References Guidelines for Prevention and Control of Hemoglobinopathies in IndiaGlobal epidemiology of haemoglobin disorders and derived service indicators - PMCLife expectancy and risk factors for early death in patients with severe thalassemia syndromes in South India - PMCSee sunoindia.in/privacy-policy for privacy information.

Dr. Amit Mehta, an oncologist joins the podcast to discuss topics in medical oncology for in this edition of the PV Roundup specialist spotlight.

Now, this podcast episode was inspired by something the host went through back in August 2022, it really scared and shock her up to say the least. Moreover the information in this podcast show comes from the website below on a government website you can check out blood disorders further for a read if you are interested in the topic at hand. https://www.womenshealth.gov/a-z-topics/bleeding-disorders#:~:text=As%20many%20as%20one%20in,may%20have%20a%20bleeding%20disorder.&text=The%Also, if you like this podcast show or any other episode you have heard on an audio diary a personal health journey feel free to leave a nice review on apple podcasts, by clicking the link below: https://podcasts.apple.com/gb/podcast/an-audio-diary-a-personal-health-journey-by-hannah-boyce/id1511505333Moreover if you would like to follow the host on her most recent social media platforms, either tiktok, you tube or twitter mostly feel free to go to the hosts website and scroll down to the bottom of the page or alternatively her name the hosts online name across the board is over forties health. https://overfortieshealth.supapass.io

 Techstination, your destination for gadgets and gear.   I'm Fred Fishkin.       Pathway to Cures is the name of a new venture philanthropy fund that is focused on providing backing to discover solutions to inherited blood disorders.    The National Hemophilia Foundation is the parent organization…where...

It is Ovarian Cancer Awareness Month and what better way to address this than having a GYN oncologist join us today? Dr. Tiffany Redfern is a gynecologic oncologist with the Center for Cancer and Blood Disorders in Fort Worth, Texas. She's a Texas girl, mom of 2 and married to a pilot. In this episode we discuss: 1. Signs and symptoms of ovarian cancer 2. Is there any screening for ovarian cancer? 3. Lifetime risk of ovarian cancer 4. Why you shouldn't ignore postmenopausal bleeding 5. BRCA screening - Who qualifies? What if you're positive? 6. Myth busting: What a Pap smear can screen for and what it can't? And more . . . . Website: https://thecentertx.com/physician/tiffany-redfern/ . . . **This is not medical advice, just medical education. Please ask your doctor medical questions as they pertain to your specific situation. Educational purposes only. #FightLikeAGirl #gyn-oncologist #cancersucks #cancereducation #medicalspecialist #cancerspecialist #femalespecialist #womendoctors #GYN #skywomenshealth . . . Dr. Carolyn Moyers, DO is a board certified OBGYN and Neuromusculoskeletal Medicine physician, and founder of Sky Women's Health, a boutique practice in Fort Worth, Texas. Welcome to the Sky Women community where we are all stronger together. COME SAY HI!!! Instagram: https://www.instagram.com/skywomenshealth Facebook: https://www.facebook.com/skywomenshealth Email: hello@skywomenshealth.com Sky Women's Health: Https://www.skywomenshealth.com 1125 S Henderson St, Fort Worth, TX 76104 To become a patient: email hello@skywomenshealth.com or call 817-915-9803. Listen to the SKY WOMEN PODCAST here: ITUNES: https://podcasts.apple.com/us/podcast/sky-women/id1541657642 SPOTIFY: https://open.spotify.com/show/79VnnWYtGJwlB7NrjBck7o?si=qWXpiBtPSS6OVOt0ki8EiQ --- Send in a voice message: https://anchor.fm/skywomen/message

Techstination interview: Pathway to Cures focused on inherited blood disorders: Dr. Kevin Mills

 On Medical Matters this evening, we talk about International Gaucher Day, which falls on 1 October and highlights the need for greater awareness of rare diseases to promote early diagnosis and we're joined by Monique Nel - Medical Advisor (Rare Diseases and Blood Disorders) at Sanofi.See omnystudio.com/listener for privacy information.

After attending a scholarship programme in France, early in his career, Prof Saliou Diop realised that a lot had to be done to improve haemophilia care in his home country of Senegal. Since then, he has been a key contributor to changing the landscape of haemophilia care in Africa over the past years, having co-authored more than 80 peer-reviewed articles, trained healthcare professionals from African countries and collaborated with numerous international experts, to share knowledge for the benefit of haemophilia and sickle cell patients. Hear from Prof Diop how haemophilia patients can benefit from an integrated management of blood disorders such as sick cell disease, in particular in regions where resources are limited.

Earlier this summer we had a chance to welcome Tara's sister Jessica Gaskell back to the podcast. Jessica is mom to our WanderLuxe Warrior, Joey, who has been fighting cancer since he was 18 months old. On our first WanderLuxe Warrior episode (which you can listen to here) covers the introduction to our childhood cancer awareness initiative and Joey and his family's story. In this episode we talk about what has happened in the past year, what is on the horizon and the recently launched "The Joey Project" which will help raise money for the Akron Children's Hospital Center for Cancer and Blood Disorders, where Joey receives treatment. Click here to learn more and donate! Follow @wanderluxedestinations for more updates on Joey!

This podcast episode continues our discussion with Dr. Aaron Gerber of Reimagine Care, a leading provider of cancer care in the home, and Dr. Clay Smith of CU Innovation Centers, the innovation and development arm of a leading health care organization.   Guest speakers: Aaron Gerber, MD, MBA Chief Executive Officer and Co-Founder Reimagine Care   Clay Smith, MD Director, Blood Disorders and Cell Therapies Center Medical Director, UCHealth and CU Innovation Centers University of Colorado   Moderator: Crystal Mullis, RN, MBA, MHA Vice President Member Backed Ventures Vizient   Show Notes: [00:43] Addressing key needs in the market [02:00] Changing an archaic approach in home care [02:44) New sophistication with proactive, at-home patient monitoring [03:42] New approach of clinical trials at a distance [04:10] Ongoing testing of the Reimagine Care model [05:17] Need for seamless monitoring and for payor recognition [06:37] The Reimagine Care model: how it works [09:43] Three main highlights in the Reimagine Care approach [11:39] Future direction   Links | Resources: Vizient Member-Backed Ventures email: mbv.info@vizientinc.com Website for Reimagine Care: www.reimaginecare.com Aaron Gerber's email: agerber@reimaginecare.com Clay Smith's email: clayton.smith@cuanschutz.edu   Subscribe Today! Apple Podcasts Amazon Podcast Spotify Google Podcasts Stitcher RSS Feed  

Guest: Nicole Vanderpool Swim Across America is a national non-profit that runs swimming-related events throughout the country to support cancer research at the most highly recognized hospitals and institutions.  Swim Across America's Denver beneficiary is Center for Cancer and Blood Disorders at Children's Hospital Colorado.  They raise money through different swim events throughout the summer.  Their big event this year is going to be on August 21st at Chatfield Reservoir.  https://www.swimacrossamerica.org/DenverSee omnystudio.com/listener for privacy information.

Making cancer care more affordable, accessible and home-centered is the goal of the partnership between Reimagine Care and CU Innovation Centers. This podcast episode highlights that partnership to show how digital technology solutions can revolutionize oncology care and bring it closer to the patient. And a leading expert from Sg2 weighs in on the latest trends that are moving toward new approaches in oncology.   Guest speakers: Aaron Gerber, MD, MBA Chief Executive Officer and Co-Founder Reimagine Care   Cory Jones, MBA Associate Principal, Sg2 Intelligence Oncology and Orthopedic Service Line Vizient   Clay Smith, MD Director, Blood Disorders and Cell Therapies Center Medical Director, UCHealth and CU Innovation Centers University of Colorado   Moderator: Crystal Mullis, RN, MBA, MHA Vice President Member Backed Ventures Vizient   Show Notes: [01:07] The state of the cancer service line and the move to the home setting [06:08] Mission of Reimagine Care and the rationale for a new approach in oncology [07:51] Strategic and financial challenges in the oncology service line [09:46] Partnership of Reimagine Care and CU Anschutz [10:45] Getting bone marrow transplant patients out of the hospital   Links | Resources: Vizient Member-Backed Ventures email: mbv.info@vizientinc.com Website for Reimagine Care: www.reimaginecare.com Aaron Gerber's email: agerber@reimaginecare.com Clay Smith's email: clayton.smith@cuanschutz.edu   Subscribe Today! Apple Podcasts Amazon Podcast Spotify Google Podcasts Stitcher RSS Feed  

Guest: Nicole Vanderpool Swim Across America is a national non-profit that runs swimming-related events throughout the country to support cancer research at the most highly recognized hospitals and institutions.  Swim Across America's Denver beneficiary is Center for Cancer and Blood Disorders at Children's Hospital Colorado.  They raise money though different swim events throughout the summer.  Their big event this year is going to be on August 21st at Chatfield Reservoir.  https://www.swimacrossamerica.org/DenverSee omnystudio.com/listener for privacy information.

In this episode we discuss a recent paper published in The Canadian Journal of Cardiology entitled Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease and co-authored by a national team of Canadian expertsWe are joined today by the two of the authors, Dr Sonia Anand and Dr. Eric KaplovitchDr. Sonia Anand is Professor of Medicine and Epidemiology, and a Vascular Medicine specialist at Hamilton Health Sciences. She holds the Canada Research Chair in Ethnic Diversity and Cardiovascular Disease (Tier 1) and is the Heart and Stroke Foundation of Ontario/Michael G DeGroote Chair in Population Health Research. Dr. Anand is a senior scientist at the Population Health Research Institute, and Director of the Chanchlani Research Centre, McMaster University. Her research focuses on the environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease, and peripheral artery disease. Dr. Anand graduated as a Doctor of Medicine from McMaster University in 1992. She completed internal medicine training at McMaster University and a Fellowship of the Royal College of Physicians and Surgeons of Canada, Ottawa, in 1996. Dr. Anand completed a thrombosis fellowship in 1997-98 under the supervision of Dr. Jeffrey Ginsberg at McMaster University, and Vascular Medicine Fellowship under the supervision of Dr. Mark Creager at the Brigham and Women's Hospital, Harvard University, Boston, USA in 2000-01. Dr. Anand received her Master's degree in clinical epidemiology in 1996 and PhD. in Health Research Methodology in 2002 under the supervision of Dr. Salim Yusuf, both at McMaster University. Dr. Anand was Principal Investigator of the WAVE trial in peripheral artery disease (PAD) patients, is the PAD Lead Investigator of the COMPASS trial, and is an executive committee member of the VOYAGER PAD trial. Dr. Anand's large-scale research programs include multi-centre prospective cohort studies and randomized trials. She has published more than 400 peer-reviewed, high-impact papers. In 2019 Dr. Anand was inducted as a Fellow to the Canadian Academy of Health Sciences. In 2021-22 Dr. Anand Co-chaired the Canadian Cardiovascular Society Peripheral Artery Disease Guidelines.ANDDr. Eric Kaplovitch completed his Internal Medicine training at the University of Toronto before completing additional Vascular Medicine and Thrombosis training at both McMaster University and the University of Toronto, as well as a subsequent fellowship at the HoPingKong Centre of Excellence with a focus on new models of care for patients with arterial and venous disease states. He currently practices Thrombosis and Vascular Medicine at the University Health Network and the Sinai Health System in Toronto and serves as the Quality and Safety Lead for the Blood Disorders program. Dr. Kaplovitch's current academic interests include optimizing the choice and intensity of vascular protective agents following severe vascular events, the organization of vascular care within local and regional health systems, as well as the teaching of vascular medicine and thrombosis to front-line clinicians. He served as co-lead for the antithrombotics section of the recent CCS guidelines on peripheral arterial disease. Follow us on Twitter: Thrombosis Canada: @thrombosiscanDr Sonia Anand: @DrSoniaAnand1Dr Eric Kaplovitch: @kaplovitchSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Today's episode is underwritten by Aflac, a proud supporter of Charting Pediatrics and Children's Hospital Colorado. For more than 20 years, Aflac has dedicated its heart and philanthropic mission to helping children with cancer. Thank you to Aflac for envisioning a world without pediatric cancer by supporting our Center for Cancer and Blood Disorders. Please visit our Charting Pediatrics website to learn more about becoming an underwriting sponsor. Pediatric cancer is a devastating diagnosis that thousands of patients and families receive a year. When faced with such a diagnosis, it is crucial that patients and families have access to the most current and effective treatment options as possible.  In the past few decades, pediatric cancer survival rates have improved immensely. Today, we are going to be discussing the treatment options, clinical trials, and the disparities and equity in pediatric oncology. Today, I am happy to be speaking with my collogues Dr. Adam Green and Dr. Kelly Faulk. Both Dr. Green and Dr. Faulk are a part of the Center for Cancer and Blood Disorders Team at Children's Hospital Colorado. Dr. Green specializes in Pediatric Oncology and is an Associate Professor of Pediatrics at the University of Colorado School of Medicine. Dr. Faulk is also an Assistant Professor of Pediatrics and specialize in pediatric Leukemia and Lymphoma, with research focused on early phase trial design and experimental therapeutics for high risk forms of leukemia.

Ms Wajiha Javaid has been working with the Haemophilia Foundation – Pakistan (HFP) since she was 16. She is currently Executive member of HFP and coordinator of the National Women’s group, which was officially formed in 2017. She shares her experience as a woman living with Von Willebrand disease and part of the core team at HFP which worked on developing the National Women’s group to provide a safe place for women to meet, exchange and learn from each other. She is proud to have seen a lot of girls empowered to blossom over the years.

Having struggled with debilitating periods for years, listen in as Fabiola shares her story of how she's overcome workplace challenges through self advocacy to allow her to now feel confident and empowered in managing her career and her bleeding disorder! Be sure to follow @vonwillebrandpuertorrican and feel free to connect with Fabiola through that page. And here are the links mentioned in today's episode: Puertorrican Association for Hemophilia and Blood Disorders https://hemofiliapr.org/english/ Helping forward financial assistance program HFA https://www.hemophiliafed.org/home/our-role-and-programs/assisting-and-advocating/financial-assistance/helping-forward/ HFA learning central - Employments Rights Course https://www.hemophiliafed.org/the-institute/   Music - reCreation by airtone (c) copyright 2019 Licensed under a Creative Commons Attribution (3.0) license. http://dig.ccmixter.org/files/airtone/59721 

CTBTA Board President Jen Pace and Dr. Michael Isakoff, Clinical Director for Connecticut Children's Center for Cancer & Blood Disorders. upcoming 9th Annual Path of Hope walk/run in Elizabeth Park this Saturday (May 14th) at 9 am. This family friendly 5K run/walk is CTBTA's flagship event, drawing up to 800 participants each year. In addition to the 5K, Path of Hope features an award ceremony honoring patients, caregivers, and medical professionals.

On this week's episode of Fast Facts - Perio Edition, Katrina Sanders, wraps up the series on Periodontitis as a Manifestation of Systemic Disease, finishing by educating us on hematologic disorders!   Quotes:    “Now, we know hematologic diseases are disorders of the blood or can be disorders of blood forming organs and this affects millions of Americans.”   “When we take a look at some of these different types of diseases, we are looking at things like blood cell cancers, hematologic diseases, including rare genetic disorders, anemias, conditions that can be related to HIV, sickle cell disease, or even in some cases, complications affiliated with chemotherapy or transfusions.”   “Recent studies that have demonstrated that bacteria like Porphomonas gingivalis does govern aspects of osteoclast differentiation, meaning that the way that our own cells, our own bone cells, are able to break down bone is readily influenced by the presence of this Gram Negative anaerobic bacteria.”   Resources:   DentistRX: https://www.dentistrx.com  More Fast Facts: https://www.ataleoftwohygienists.com/fast-facts/    Katrina Sanders Website: https://www.katrinasanders.com  Katrina Sanders Instagram: https://www.instagram.com/thedentalwinegenist/    Papapanou, P. N., Sanz, M., Buduneli, N., Dietrich, T., Feres, M., Fine, D. H., ... & Tonetti, M. S. (2018). Jepsen S, Caton JG, Albandar JM, Bissada NF, Bouchard P, Cortellini P, Demirel K, de Sanctis M, Ercoli C, Fan J, Geurs NC, Hughes FJ, Jin L, Kantarci A, Lalla E, Madianos PN, Matthews D, McGuire MK, Mills MP, Preshaw PM, Reynolds MA, Sculean A, Susin C, West NX, Yamazaki K. Periodontal manifestations of systemic diseases and developmental and acquired conditions: Consensus report of workgroup 3 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S237-S248. doi: 10.1002/JPER.17-0733. PMID: 29926943.   Botelho, J., Machado, V. & Mendes, J.J. Periodontal Health and Blood Disorders. Curr Oral Health Rep 8, 107–116 (2021). https://doi.org/10.1007/s40496-021-00301-w

On this week's episode of Fast Facts - Perio Edition, Katrina Sanders, wraps up the series on Periodontitis as a Manifestation of Systemic Disease, finishing by educating us on hematologic disorders!   Quotes:    “Now, we know hematologic diseases are disorders of the blood or can be disorders of blood forming organs and this affects millions of Americans.”   “When we take a look at some of these different types of diseases, we are looking at things like blood cell cancers, hematologic diseases, including rare genetic disorders, anemias, conditions that can be related to HIV, sickle cell disease, or even in some cases, complications affiliated with chemotherapy or transfusions.”   “Recent studies that have demonstrated that bacteria like Porphomonas gingivalis does govern aspects of osteoclast differentiation, meaning that the way that our own cells, our own bone cells, are able to break down bone is readily influenced by the presence of this Gram Negative anaerobic bacteria.”   Resources:   DentistRX: https://www.dentistrx.com  More Fast Facts: https://www.ataleoftwohygienists.com/fast-facts/    Katrina Sanders Website: https://www.katrinasanders.com  Katrina Sanders Instagram: https://www.instagram.com/thedentalwinegenist/    Papapanou, P. N., Sanz, M., Buduneli, N., Dietrich, T., Feres, M., Fine, D. H., ... & Tonetti, M. S. (2018). Jepsen S, Caton JG, Albandar JM, Bissada NF, Bouchard P, Cortellini P, Demirel K, de Sanctis M, Ercoli C, Fan J, Geurs NC, Hughes FJ, Jin L, Kantarci A, Lalla E, Madianos PN, Matthews D, McGuire MK, Mills MP, Preshaw PM, Reynolds MA, Sculean A, Susin C, West NX, Yamazaki K. Periodontal manifestations of systemic diseases and developmental and acquired conditions: Consensus report of workgroup 3 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S237-S248. doi: 10.1002/JPER.17-0733. PMID: 29926943.   Botelho, J., Machado, V. & Mendes, J.J. Periodontal Health and Blood Disorders. Curr Oral Health Rep 8, 107–116 (2021). https://doi.org/10.1007/s40496-021-00301-w

As you know March is officially “Bleeding Disorder Awareness Month.” I have decided to talk about the complex and fascinating subject of hematology. I will pick where I left off discussing one more type of anemia and then what we can do health wise in regard to the many types of anemia. Then I will discuss blood disorders & blood cancers. Hematology: How to Live Healthy with Blood Disorders Part 2. Below are the links that I promised during the podcast. http://www.fanconi.org/ https://www.hematology.org/education/patients/anemia/iron-deficiency https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/livinghealthy/message Support this podcast: https://anchor.fm/livinghealthy/support

Thank you for tuning in to the Living Healthy Podcast. I have another phenomenal show lined up for you this evening. March is officially “Bleeding Disorder Awareness Month.” So I decided to do a 2 part series on blood disorders and cancers that are associated with hematology. This is part 1 of a 2 part series. The first part of this podcast focuses on the different types of anemia and treatment as well what you can do health wise in dealing with the ailment. In part 2, I cover blood cancers and other blood disorders including treatment and healthy decisions you can make. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/livinghealthy/message Support this podcast: https://anchor.fm/livinghealthy/support

Please tune in to watch and listen to Episode 42 of The Lebanese Physicians Podcast with Dr. Adlette Inati, and co-hosted by Dr. MohammadAli Jardali. In this episode, we discuss the Georges Nassim Khoriaty Foundation focusing on its establishment, and its work on improving the lives of children with blood cell disorders and cancers in Lebanon. The foundation has done tremendous work advancing research in sickle cell disease in Lebanon including newborn screening, and Thalassemia. We would also be remiss if we do not mention its great work promoting road safety in Lebanon. You can donate to the foundation on: gnkfoundation.org You can also follow it on facebook, instagram, and LinkedIn. You can listen to the podcast also on the following links:   Apple: https://podcasts.apple.com/us/podcast/the-lebanese-physicians-podcast/id1545290394?i=1000549394792   Spotify: https://open.spotify.com/episode/3nGL3sFO6ueTqOEfs1H176?si=v5ovRNt9Sx2bjR5OkQgGpw   You can watch the episode on YouTube: https://youtu.be/y32wUsKpqPg #Sicklecelldisease #Thalassemia #Blooddisorders #roadsafety #Lebanon

Many young women and adolescents experience heavy or abnormal menstrual cycles. Typically, if a cycle lasts longer than 8 days, it is considered abnormal. Some other abnormalities include bleeding that occurs more than every three weeks and cycles that require one to change products every hour or less during menstruation. These symptoms can also cause fatigue, dizziness, or other signs of anemia. In today's episode, we are going to unpack and inform providers on how to best support young women in their practices that have abnormal menstrual cycles.  Dr. Huguelet is the Section Chief for the Division of Pediatric and Adolescent Gynecology and the Fellowship Program Director at Children's hospital Colorado. Dr. Moyer is part of the Hematology/ Oncology internal Medicine team at Children's and is also an Assistant Professor at the University of Colorado School of Medicine. Both Dr. Huguelet and Dr. Moyer run the “Spots and Dots Clinic” here at Children's. Do you have thoughts about today's episode or suggestions for a future topic? Write to us, Chartingpediatrics@childrenscolorado.org. 

The Female Adolescent Bleeding (FAB) Clinic at Children's of Alabama is a partnership between doctors in Adolescent Medicine and Pediatric Hematology at Children's of Alabama. FAB helps treat painful, heavy periods that may keep young women from participating in activities. Some are afraid to talk about it, but their lives are disrupted every month. Certain issues can be corrected with hormonal balance, and others could signal a serious blood disorder that needs attention and follow up by a specialist.

Dr. Jennifer Cox(Oncologist - Children

The St. Baldrick's Foundation, the largest charitable funder of childhood cancer research grants, and the American Cancer Society, a health organization dedicated to eliminating cancer, formed a partnership in 2019 to fund grants that will accelerate childhood cancer research with the goals of understanding and discovering new treatment options and improving care and survival in children with cancer. Kathleen Ruddy, St. Baldrick's Foundation CEO, joined the podcast to talk through the goals of this unique partnership. “Why do some patients respond better than others to a particular treatment? Why does one treatment cause more late effects than another? What else can we learn to speed up progress, to cure more children, more effectively, and less harshly?” Then two of the grantees who have been funded through the partnership talked about what they hope to accomplish. Yael P. Mossé, MD, is Associate Professor of Pediatrics at the University of Pennsylvania and Director of the Neuroblastoma Developmental Therapeutics Program, as well as a pediatric oncologist at The Children's Hospital of Philadelphia. Dr. Mossé's grant is focused on improving patient outcomes for ALK mutant neuroblastoma through precision molecular targeting. E. Anders Kolb, MD, is Vice Chairman for Research and Professor in the Department of Pediatrics at Sidney Kimmel Medical College at Thomas Jefferson University, as well as Director of the Nemours Center for Cancer and Blood Disorders at Nemours/Alfred I. duPont Hospital for Children. Dr. Kolb's study aims to validate the detection of novel biomarkers for the Pediatric Acute Leukemia (PedAL) Initiative Sub-trials. 0:00 – Kathleen Ruddy, CEO of St. Baldrick's Foundation 10:25 – Yael P. Mossé, MD, and E. Anders Kolb, MD 11:29 – Drs. Mossé and Kolb on why, “in pediatric cancer care, clinical trial participation is the standard of care” 13:31 – Dr. Mossé on how her team is “bringing the science to the patient” to learn how children with neuroblastoma respond (or don't respond) to treatments 15:57 – Dr. Kolb on why it's so important, and challenging, to bring precision medicine approaches to childhood cancer treatment 18:37 –Dr. Mossé explains the goal “to bring the science to the clinical trials in real time and not for there to be a lag” 21:38 – Dr. Kolb highlights how revolutionary it is for Dr. Mossé to change a clinical trial based on data emerging in the lab 23:26 – Dr. Kolb explains how “the AML that kids get is nothing like the AML that older adults get” and why this matters for drug development 27:43 – “We as pediatricians are taught early on,” notes Dr. Mossé, “that kids are not small adults, and it really is the same for pediatric cancer.” 30:17 – Dr. Kolb on the inspiration he drew from an initiative by St. Baldrick's Foundation called Project:EveryChild, and describes his new study: “what we hope is that we will be as successful in relapse as we have been in newly diagnosed AML” 32:25 – Dr. Mossé on the value of collecting tissue over time, including at relapse, and how a major part of her new study is using liquid biopsies to collect samples in a less invasive way 34:43 – Dr. Kolb on the impact of this funding: “If we're successful, we're going to be able to rapidly screen for relevant biomarkers and we're going to be able to enroll kids in the therapy that has the highest potential to provide benefit.” 37:46 – Dr. Mossé describes how this funding will support her research: “My hope and my expectation is to make a really big difference for a small subset of patients. I think that's where cancer biology has turned now—one disease is not defined by its histology; it's defined by its underlying molecular biology.” 40:29 – A message they'd like to share with children going through cancer treatment and with their parents and families

In her role as the Director of the Supportive Care Clinic at the Aflac Cancer and Blood Disorder Center in Atlanta, Dr. Katharine Brock wears many hats. Dr. Brock will talk about this critical role for pediatric cancer patients and their families that she serves in trying to make certain that each day for these children and adolescents is better than the day before.Dr. Brock will also talk about the difference between Palliative Care (Which is a synonym for Supportive in this case) and Hospice Care, as well as being chosen as the winner of the very prestigious Hastings Center Cuniff-Dixon Physician award . This award was given to her for technical competence, personal Integrity, and the ability to function well as part of a care team. This clinic was started just a few years ago, and will be making a positive impact for these children and families for many years to come. 

Dr. Qin Zhang is a board-certified medical oncologist at Peeples Cancer Institute in Dalton, Georgia. For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit HamiltonHealth.com/cancer. This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Bernie Gehris is a father of three who lost his son to cancer. He learned about the Courage Classic benefiting Children's Hospital of Colorado from their family's pediatrician and has been riding it ever since!  Through the 30+ years since the ride began, a dedicated team has arisen to fundraise specifically for the Center for Cancer and Blood Disorders. Now he has even more motivation to ride!Physical activity can be therapeutic and it certainly has been for myself, Bernie, and countless others. If you're interested in learning more about the Courage Classic go to couragetours.com to find out how to donate or register to ride.

In this podcast, Contributing Editor Dr. Sarah Tasian has a conversation with Dr. Yoram Unguru. They discuss Dr. Tasian's Feature article from the July/August 2021 issue of The Hematologist, titled, "Chemotherapy Drug Shortages in Pediatric Oncology: A Global Public Health Crisis Threatening Our Children." They shed light on chemotherapy drug shortages currently affecting pediatric cancer patients. You can access her Feature article online at https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V18.4.2021412/476169/Chemotherapy-Drug-Shortages-in-Pediatric-Oncology. Additional ASH affiliation and COI information: Dr. Sarah Tasian serves on the Educational Program Advisory Panel for the 2021 ASH Annual Meeting and is a member of the Scientific Committee on Blood Disorders in Childhood. Dr. Tasian receives/d research funding from Incyte Corporation and Gilead Sciences and serves on the scientific advisory boards for Aleta Biotherapeutics and Kura Oncology. Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

Kerry Ann Currenti is a survivor of Ovarian Cancer, 4 blood disorders, Lupus and many more health issues. She was given 10 years to live in 1987 and through the power of Jesus she is still here. Kerry is in Medical journals, appeared on Dr OZ and much more sharing her crazy story of sickness, healing, her outer body experience and more. Sound of Heaven radio is live every Wednesday and Friday at 6pm on 103.9 FM. You can visit Sound of Heaven every Sunday at 10:30am. Go to www.soh.church. If you are not from the NY area, we got you covered! Visit our Digital Online Church Platform.Support the show (https://tithe.ly/give_new/www/#/tithely/give-one-time/440033)

In this episode of Real World Talk, Nick Gritter talks to Barry Russo, CEO of The Center for Cancer and Blood Disorders. They discuss the benefits and challenges of value-based care (VBC), an approach that takes into account every aspect of a patient's health instead of focusing on just one issue, like cancer. Getting enough data in a timely manner is one of the biggest challenges. “We can't keep track of everything going on without information and data: We can't look at trends, we can't identify opportunities without really good data,” Russo says. Real world data often analyzes outcomes drug manufacturers overlook, such as patients' quality of life. “Having that outcome-based data is incredibly helpful in ensuring that you're making good decisions for the patients, but also cost-effective decisions,” Russo says. They also talk about the unique challenges of providing VBC in oncology settings, and Russo explains his concerns about COVID's long-term impact on cancer treatment, and what the Center is doing to keep patients safe. Episode Key Points Value-based care monitors every aspect of a patient's experience. Where oncology clinics typically focus only on treating cancer, value-based care encompasses every aspect of a patient's health. Risk assessment tools and a clinical pathway model help the Center's oncologists constantly check in with patients and standardize medical decisions. Each clinic has a triage site to help manage patients' symptoms and toxicities, which are sometimes deprioritized under other approaches. It takes a village to do value-based care. Looking at every health issue a patient is experiencing means connecting with other specialists, including physiotherapists, dieticians, social workers and genetic counselors. Since cancer care tends to be long term, it's more likely that cancer patients will also experience other health problems while under the care of their oncologists, compared to patients with acute conditions. This is one complication of value-based care in oncology. Oncologists value the insights real world data offers. Many of the cancer treatments used today have been around for a long time, so there aren't many new studies into them. Real world data provides an updated look at these treatments. In addition, real world data can look into outcomes that oncologists are really interested in but drug companies often don't study, such as a patient's quality of life and the long-term impacts of different medications. Episode Highlights [00:22] Introduction — Nick Gritter introduces Barry Russo, CEO of The Center for Cancer and Blood Disorders. [01:48] Value-based care — Russo explains that VBC has evolved into working on a patient's entire medical experience (and the cost of that) rather than simply focusing on treating their cancer. [03:24] How to do VBC — To do VBC, the Center had to set up an infrastructure to follow each patient and monitor their needs. For example, using clinical pathways that standardize processes, risk assessment tools, and electronic care to improve communication. [08:04] VBC benefits — Russo believes that a VBC approach offers a better standard of care to patients. Every aspect of their health is tracked, including issues outside oncology, and the Center communicates more effectively with other specialists. [10:44] Data challenge — One of the biggest challenges of VBC is getting data fast enough to make real-time decisions, especially on the payer side. [12:00] It takes a village — Another challenge of VBC is maintaining effective communication between the many experts the approach requires, who aren't involved when the focus is only on oncology. For example, dieticians, social workers, physiotherapists and cardiologists. [14:12] VBC will become the standard — Given that VBC is likely to become the standard approach to healthcare one day, it's better to implement it now and work through the various obstacles than get left behind. [17:04] RWD for VBC — Russo appreciates real world data because in many cases, cancer treatments are so established that there are no new clinical trials studying them. And the results go beyond the theoretical. [20:31] VBC for cancer — VBC oncology programs differ from those in other areas of medicine because the patient is under their care for longer. Patients are likely to experience non-oncological health issues during this time, which the oncology team is still responsible for managing. [24:37] Cancer is missed under COVID — The COVID-19 pandemic has seen drastic reductions in the rates of screenings for various cancers, which means cancers aren't being caught at the early stages, leading to a worrying rise in late-stage cases that are harder to treat (and more complex for VBC systems.) [26:57] Protective measures — The Center has introduced multiple precautions to keep patients safe at their clinics, including a touch-free COVID screening process before entry, UV filtration systems, limited telemedicine, and improved electronic communications. [33:19] The post-COVID clinic — Russo says the Center will likely keep some of the COVID measures even when the pandemic is over. For example, touch-free temperature checks, the UV filtration system, and more consistent electronic communication with patients. Resources Nick Gritter Barry Russo